Immuneering launches Phase 3 MAPKeeper 301 trial of atebimetinib in first‑line metastatic pancreatic cancer
Immuneering Corporation presented the design of its global Phase 3 MAPKeeper 301 study at the ESMO Congress in Madrid. The open‑label trial randomises patients 1:1 to atebimetinib 320 mg daily plus modified gemcitabine/nab‑paclitaxel versus standard gemcitabine/nab‑paclitaxel, with overall survival as the primary endpoint. Dosing began in June and the study is now recruiting. The trial builds on Phase 2a data that showed a median overall survival of 17.3 months in 55 patients.
Why it matters
The company says positive Phase 3 results could materially affect IMRX’s share price, as investors will price in the potential survival benefit ().
Key facts
- 1The trial is named MAPKeeper 301 and is a global, randomized, open‑label study (). investing.com
- 2Patients are randomised 1:1 to atebimetinib 320 mg orally once daily plus modified gemcitabine and nab‑paclitaxel, or standard gemcitabine and nab‑paclitaxel (). investing.com
- 3The primary endpoint is overall survival (). investing.com
- 4Dosing of patients started in June 2026 (). investing.com
- 5The study is currently recruiting (). investing.com
- 6Phase 2a results in 55 patients showed median overall survival of 17.3 months, median progression‑free survival of 8.3 months, objective response rate of 36% and disease‑control rate of 82% (). investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.